HOME >> BIOLOGY >> NEWS
Blood markers may reflect newborns' potential of contracting HIV

Preventing HIV-infected pregnant women from transmitting the virus to their newborns has long been a major concern for obstetricians. As such, many doctors continue to debate the benefits of elective Caesarian section as a way to protect the infant.

In high-risk pregnancies, where the viral loads can't be suppressed with medication, delivering a baby by C-section directly from the protected, sterile environment of the amniotic sac can limit the risk of HIV transmission. But in lower-risk pregnancies, where antiretroviral medications keep the virus in check, the risk of transmitting HIV to a newborn is only about 1 percent to 2 percent.

A new study by researchers at Johns Hopkins and the National Institutes of Health demonstrates that uncomplicated labor and vaginal delivery does not stimulate the babies' immune systems. Results are scheduled to be presented Jan. 18 at the annual meeting of the Society for Maternal-Fetal Medicine in New Orleans.

A research team led by Hopkins obstetrician Helene Bernstein, M.D., Ph.D., studied lymphocytes from the umbilical cords of 23 babies born by vaginal delivery or elective C-section, as well as cells taken from eight babies born to mothers who had chorioamnionitis (a bacterial infection of the amniotic sac) or preterm labor.

None of the women had HIV. Checking for specific biochemical markers of white blood cell activation, they found the level of cell activity to be similar among babies born by either method. In addition, when HIV was introduced to these cells in the laboratory, there was no difference in their ability to be infected.

However, the babies born to mothers with chorioamnionitis or preterm labor did show activation of their white blood cells. When HIV was introduced to the white blood cells in the laboratory, there were more infections and the virus grew quickly, meaning that these infants could be at higher risk for HIV transmission if born to HIV-infected mothers with
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
18-Jan-2002


Page: 1 2

Related biology news :

1. Blood pressure hormone may inhibit growth of lung cancer
2. Blood tests identify patients on dialysis at high risk for death from cardiovascular disease
3. Blood banking systems improving in China, more progress needed
4. Blood proteins tied to inflammation
5. Bloodworms way with copper likely provides paradigm for new materials
6. Blood stem cells carry targeted genes
7. Blood vessels trigger development of the pancreas
8. Blood vessels found to signal chain of destruction in bone diseases
9. Blood markers associated with autism and mental retardation
10. Blood test for diagnosing schizophrenia
11. Blood pressure-lowering DASH diet also reduces homocysteine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: